美國居民不適用 XM 服務。

Smith & Nephew shares soar as activist Cevian builds stake



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Smith & Nephew shares surge on activist Cevian building stake</title></head><body>

Cevian's 5% stake to make it no.2 shareholder in S+N

S+N shares rise to top of FTSE 100

Cevian sees potential by improving operating performance

S+N says will continue talks with Cevian

Adds analyst quote in paragraphs 10-11

By Yadarisa Shabong

July 4 (Reuters) -Shares in Smith & Nephew SN.L rose 7% to the top of the FTSE 100 index on Thursday after activist investor Cevian Capital disclosed a 5% stake in the British medical equipment maker, a filing showed.

Cevian, whose newly disclosed holding would make it Smith & Nephew's second largest shareholder according to LSEG data, is known for taking stakes in companies and calling for change.

Smith & Nephew, which makes orthopaedic implants, wound dressings and other surgical materials, has lost more than 50% of its stock value from an all-time high hit in February 2020.

Pandemic lockdowns that led to surgery delays and supply-related disruptions from COVID times, as well as high raw material costs due to the Russia-Ukraine conflict, have taken a toll on the company, which has struggled to grow its margins.

"Smith & Nephew owns fundamentally attractive businesses in structurally growing markets, but the company has not generated shareholder value for many years," Friederike Helfer, a partner at Cevian Capital, said in a statement.

"Cevian sees the potential to create significant long-term value by improving the operating performance of the company’s businesses. We have high expectations for the board and management to realize this potential," he added.

Smith & Nephew's FTSE 100 shares have struggled to eke out yearly gains for the past four years.

The group said it would continue to engage with Cevian "as we dowith all of ourshareholders", without providing further details as the conversations are private.

In 2022, it started a transformation plan that aimed to grow its hip and knee implant, wound management and sports medicines businesses while expanding margins.

"Cevian is likely to hold management's feet to the fire and may look for more ambitious targets than set out under the existing improvement plan," AJ Bell analyst Russ Mould said.

"It could also push for a rationalisation of the company’s portfolio."

Cevian is No.3 shareholder in Irish building materials firm CRH CRH.N, which last year ditched its primary London listing in favour of New York.

It is also the top shareholder in global education group Pearson PSON.L, which had reportedly faced investor pressure last year to move its listing.

Cevian sold down its entire stake in British insurer Aviva AV.L last year and ended its campaign to drive up investor payouts at the FSTE 100 company.

Smith & Nephew shares were up 7% to 1,057 pence by 1016 GMT.



Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman, Nivedita Bhattacharjee and Jan Harvey

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明